和铂医药与辉瑞合作展示MesoC2临床研究设计

财中社
23 May

5月23日,和铂医药(02142)发布公告,宣布其合作伙伴辉瑞将在2025年6月2日的美国临床肿瘤学会(ASCO)年会上展示MesoC2(HBM9033/PF-08052666)的首次人体1期临床研究设计。MesoC2是一种靶向人间皮素(MSLN)的抗体偶联药物,旨在评估其在晚期实质瘤患者中的安全性和耐受性。根据公告,MesoC2由公司的全资附属公司诺纳生物自主研发,并已于2023年12月通过全球...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10